![Insights from 2023 ASH Annual Meeting](http://media.vumedi.com/thumbs/channel_logo/2023/12/d8f4a042-951d-471d-8892-527b15ad5587.png.200x0_q85.png)
Insights from 2023 ASH Annual Meeting
Prevalence and Prediction of Ruxolitinib Treatment Emergent Thrombocytopenia in Myelofibrosis
By
Insights from 2023 ASH Annual Meeting
FEATURING
Douglas Tremblay
By
Insights from 2023 ASH Annual Meeting
FEATURING
Douglas Tremblay
Login to view comments.
Click here to Login